ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients (EPO-TRAUMA)

Trauma — such as serious car accidents, falls, or other major injuries — is a leading cause of death and long-term disability worldwide. Critically injured patients who need to be put on a breathing machine (mechanical ventilation) in the intensive care unit (ICU) are at high risk of complications. Despite advances in trauma care, many patients still die or survive with severe disabilities. Epoetin alfa (also known as erythropoietin) is a medication that stimulates the production of red blood cells. Research has suggested it may have broader protective effects on the body beyond just making blood cells — including protecting organs and potentially improving survival in critically ill patients. The EPO-TRAUMA trial is an international study testing whether giving epoetin alfa to critically ill trauma patients reduces the rate of death and severe disability. You may be eligible if you are aged 18–75, have been critically injured within the last 24 hours, require mechanical ventilation in the ICU, and are expected to remain in the ICU for at least 48 hours. Because this is an emergency situation, consent may be provided by a legal representative. Patients with a history of blood clots, those already on blood-thinning medications, pregnant patients, or those expected to die within 24 hours would not be eligible.